ICPE Annual Conference
August 23–27, 2023
Halifax, Nova Scotia | Halifax Convention Centre
Improve your understanding of the safety and effectiveness of drugs and biologics in the real world
We’re excited to connect and collaborate with you during the International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE). With decades of pharmacoepidemiology experience, our research team brings scientific rigor to protocol development, study design, project execution and reporting. Learn more about our work by attending one of our multiple presentations or meet with us at Booth 604-605.
Meet our experts
John D. Seeger, PharmD, DrPH
Chief Scientific Officer
In addition to his role with Optum, Dr. Seeger is adjunct faculty at the Harvard T.H. Chan School of Public Health. He has authored or co-authored over 100 articles and is a Fellow of the International Society for Pharmacoepidemiology.
Florence T. Wang, ScD
Vice President, Epidemiology
Dr. Wang’s work is in the areas of vaccines, maternal and infant outcomes, neurology, oncology and cardiovascular disease.
Andrea K. Chomistek, MPH, ScD
Senior Scientist
Dr. Chomistek leads studies in the areas of endometriosis, osteoporosis, pregnancy, migraine and circulation.
Jessica M. Franklin, PhD
Principal Consultant, RWE
Dr. Franklin has extensive experience designing and leading studies of the effectiveness, safety and utilization of medications from large health care databases, including claims and electronic health records.
See our experts’ research contributions
Pre-conference Skills Course | 2:00–6:00 p.m.
Propensity Scores in Pharmacoepidemiology
John D. Seeger, PharmD, DrPH – Optum
Jeremy A. Rassen, ScD – Aetion
Issues of bias and confounding relate to study design and analysis in the setting of non-random treatment assignment where compared subjects might differ substantially with respect to comorbidities. Failing to address a lack of balance in the covariates between treated and comparison groups can produce confounded estimates of treatment effect. This course aims to describe the use of propensity scores to address confounding in pharmacoepidemiology.
Symposia & Workshops: Session 2 | 10:30 a.m.–12:00 p.m.
Curriculum in Pharmacoepidemiology Training and Alignment with Updated Core Competencies: State of the Field and Educational Needs Assessment
Oral Presentations: Session 2 - Vaccine Potpourri | 5:15–5:30 p.m.
The Contribution of Immunization Information System Data to Claims-Based Capture of Vaccines Used to Prevent Mpox and Implications for Claims-Based Mpox Surveillance
Poster Session A | 8:00 a.m.–6:00 p.m.
Characterization of U.S. Adults Aged 18–64 Years Vaccinated Against Mpox within the Food and Drug Administration Biologics Effectiveness and Safety (BEST) Initiative
Development and Validation of a Claims-based Algorithm for Moderate-to-Severe Atopic Dermatitis
Development and Validation of Claims-based Algorithms for Conjunctivitis and Keratitis
Medical chart review of selected adverse event of special interest (AESI) to support rapid safety assessment of JCOVDEN vaccine: a validation study using US electronic health records and claims data
Monitoring Results From a Postapproval Safety Study of Pfizer-BioNTech COVID-19 Vaccine in the United States: Vaccine Utilization and Incidence Rates of Myocarditis/Pericarditis
Pregnancy during a pandemic: pregnancy occurrence and outcomes during the SARS-CoV-2 pandemic
Use of Janssen Ad26.COV2.S COVID-19 Vaccine (JCOVDEN) and mRNA COVID-19 Vaccines in Four Large US National Insurers
Use of US Health Insurance Claims Data to Determine Cause of Death
Validation of a Claims-based Algorithm for Myocarditis/Pericarditis using Medical Chart Review
Oral Presentations: Session 4 - Vaccines: Boosting Confidence | 1:00–1:15 p.m.
Effectiveness of BNT162b2 COVID-19 Vaccine in US Children Aged 5-17 Years
Oral Presentations: Session 4 - Lightning Session 2 | 2:10–2:15 p.m.
The Contribution of Immunization Information System Data to Claims-Based Vaccine Administration Capture Over Time and Implications for Claims-Based COVID-19 Vaccine Studies
Symposia & Workshops: Session 3 | 4:15–5:45 p.m.
Building Consensus on RWE Evaluation: Standardized Tool for Assessing Validity in RWE studies of Medication Safety and Effectiveness
Poster Session B | 8:00 a.m.–6:00 p.m.
Use of Very Low-Dose Vaginal Estrogens Among Postmenopausal Women in the US
Oral Presentations: Session 6 - Vaccines: Timing is Everything | 1:30–1:45 p.m.
Are Major Congenital Malformations (MCMs) Identifiable Among Claims for Non-Live Births?
Oral Presentations: Session 6 - Lightning Session 2 | 2:10–2:15 p.m.
Safety Monitoring of BNT162b2 (Pfizer-BioNTech) COVID-19 Vaccines in U.S. Children aged 5-17 years
Poster Session C | 8:00 a.m.–1:30 p.m.
Effectiveness of Monovalent COVID-19 Booster/Additional Vaccine Doses in the United States
Factors Associated with Health Plan Disenrollment During Pregnancy Among US Commercially Insured Women
Validation of a Claims-based Algorithm for Myocarditis/Pericarditis in Pediatric Patients
Capabilities to answer a variety of research questions
Optum Epidemiology overview
Advance public health and safety with our trusted epidemiologists
Understanding maternal health outcomes
The Optum® Dynamic Assessment of Pregnancies and Infants links women and their infants’ data to answer questions about maternal health.
Leveraging external control arms
Optum Epidemiology can develop and execute external control arm studies, an emerging real-world evidence (RWE) option.
Optum Epidemiology publications
